Nervous System & Special Senses

Cognitive screening: USPSTF position and screening tools

Clinical Overview and When to Suspect Cognitive Impairment

— Does NOT recommend against screening; clinicians may screen based on clinical judgment

— Distinct from Medicare Annual Wellness Visit (AWV), which mandates detection of cognitive impairment as part of the visit (no specific tool required)

— Patient or family reports memory complaints, repeating questions, missed appointments, getting lost

— Functional decline: medication errors, mismanaged finances, missed bills, motor vehicle incidents

— New depression, apathy, personality change, or psychosis in older adult

— Poor adherence to chronic disease regimens that were previously well-managed

— Delirium episode (which doubles long-term dementia risk and warrants reassessment 1–3 months after resolution)

Board pearl: USPSTF gives cognitive screening an I (insufficient evidence) grade, but the Medicare AWV requires assessment for cognitive impairment — these two facts coexist and are both testable. Step 3 favors case-finding (screen when symptoms or concerns arise) over universal screening.

Cognitive impairment spans a spectrum from subjective cognitive decline → mild cognitive impairment (MCI) → dementia (major neurocognitive disorder), with Alzheimer disease being the most common etiology in older adults

USPSTF position (2020, reaffirmed stance): Current evidence is insufficient (I statement) to assess the balance of benefits and harms of screening for cognitive impairment in community-dwelling adults ≥65 who are asymptomatic

When to suspect / when screening is clinically indicated (regardless of USPSTF I statement):

Epidemiology: ~1 in 9 Americans ≥65 has Alzheimer dementia; MCI prevalence ~15–20% of those ≥65; ~50% of dementia is undiagnosed in primary care

Reversible/contributing factors to evaluate before labeling "dementia": B12 deficiency, hypothyroidism, depression ("pseudodementia"), polypharmacy (anticholinergics, benzodiazepines), OSA, alcohol use, normal-pressure hydrocephalus

Presentation Patterns and Key History

— Memory (amnestic): forgetting recent conversations, repeating questions, misplacing items → suggests Alzheimer disease pattern

— Executive/attention: trouble planning, multitasking, finances → vascular, frontotemporal, or Lewy body

— Language: word-finding, naming, comprehension → primary progressive aphasia, AD variant

— Visuospatial: getting lost in familiar places, misjudging distances → posterior cortical atrophy, DLB

— Behavioral/personality: disinhibition, apathy, hyperorality → behavioral-variant FTD (typically age 50–65)

— Insidious, years → Alzheimer, FTD

— Stepwise decline with vascular events → vascular dementia

— Fluctuating cognition + visual hallucinations + parkinsonism → DLB

— Days–weeks (subacute) → consider prion disease, autoimmune encephalitis, NPH, metabolic

— Hours–days with inattention → delirium until proven otherwise (never screen for dementia during delirium)

— Validated informant tool: AD8 (≥2/8 suggests impairment, sensitivity ~84%)

— IADLs decline first: finances, medications, transportation, shopping, cooking, telephone

— ADLs decline later: bathing, dressing, toileting, feeding

— MCI = cognitive deficit WITHOUT functional impairment; dementia = cognitive deficit WITH functional impairment

Key distinction: MCI vs dementia is decided on function, not test score. A patient with a low MoCA who still pays bills and drives safely has MCI; a patient with mild deficits who can no longer manage medications has dementia.

Cardinal complaint categories to triage on history:

Tempo matters:

Collateral history is mandatory — patients with dementia often have anosognosia (lack of insight) and underreport deficits; an informant interview (spouse, child) is the single highest-yield data point

Functional assessment (drives diagnosis of dementia vs MCI):

Risk-factor history: age, family history, APOE4, education level, vascular risk (HTN, DM, AF, smoking), prior TBI, hearing loss, depression, alcohol, sleep apnea

Physical Exam Findings (and Functional/Mental Status Assessment)

— Orthostatic hypotension → DLB, autonomic neuropathy, or medication effect

— Bradycardia/weight gain → hypothyroidism

— Cachexia or B12 stigmata (glossitis, pallor) → nutritional contributor

— Parkinsonism (bradykinesia, rigidity, rest tremor): DLB if cognitive symptoms precede or parallel motor; PD dementia if motor precedes by ≥1 year

— Gait apraxia ("magnetic gait") + urinary incontinence + cognitive decline → classic NPH triad ("wet, wobbly, wacky")

— Focal deficits, hyperreflexia, pseudobulbar affect → vascular dementia

— Myoclonus + rapidly progressive → CJD (prion)

— Frontal release signs (grasp, snout, palmomental): nonspecific but support frontal pathology

— Vertical gaze palsy + axial rigidity + falls → PSP

— Hearing loss is the single largest modifiable midlife risk factor for dementia (Lancet Commission); always test and consider amplification

— Vision: cataracts, macular degeneration mimic cognitive decline

— Level of arousal/attention (rule out delirium first via inattention: digit span, days of week backward)

— Orientation, registration, recall, language, visuospatial (clock draw), executive (Luria sequences)

Step 3 management: Always screen for delirium and depression BEFORE diagnosing dementia. A patient with acute inattention should not be labeled with dementia until delirium is excluded; treating depression may unmask reversible cognitive deficits.

General exam goals: detect contributing/reversible factors and identify dementia subtype clues

Vitals and general:

Neurologic exam — subtype clues:

Sensory screening (critical and frequently neglected):

Mental status exam — what to document:

Depression screen: PHQ-2/PHQ-9 — depression can mimic ("pseudodementia") or coexist with dementia; up to 40% of patients with dementia have comorbid depression

Diagnostic Workup — Screening Tools and Initial Office Assessment

— 3-item recall + clock-draw

— Score: 0–2 recalled or abnormal clock = positive screen

— Sensitivity ~76–99%, minimal language/education bias, free

— Often the right answer on Step 3 for a brief office screen

— <26 abnormal (add 1 point if ≤12 years education)

— More sensitive than MMSE for MCI and executive dysfunction

— Requires certification (free version still available); multiple language versions

— <24 abnormal; insensitive to mild/executive deficits; copyrighted

— Heavily influenced by education and language

— CBC, CMP, TSH, vitamin B12 (universal)

— Consider: HIV, RPR, folate, homocysteine, methylmalonic acid in selected patients

— Depression screen (PHQ-9)

— Non-contrast MRI brain (preferred) or CT if MRI contraindicated — once per workup to exclude tumor, subdural, stroke, NPH, hydrocephalus, severe vascular disease

— Pattern of atrophy: medial temporal/hippocampal → AD; frontotemporal → FTD; generalized + ventriculomegaly out of proportion to atrophy → NPH

Board pearl: A positive screening test is NOT diagnostic — it triggers a formal workup. The diagnosis of dementia remains clinical, integrating cognitive testing, function, labs, and imaging.

No single "gold standard" screening tool; tool choice depends on time, language, and education level

Mini-Cog (3 minutes) — preferred in busy primary care

MoCA (Montreal Cognitive Assessment) — 10 minutes, score /30

MMSE (Folstein) — 5–10 minutes, /30

SLUMS (St. Louis University Mental Status) — similar to MoCA, free, useful in VA settings

GPCOG, Memory Impairment Screen, AD8 — alternatives; AD8 is informant-based, ideal when patient lacks insight

Initial labs after positive screen (per AAN/ACR appropriateness):

Initial imaging:

Diagnostic Workup — Advanced or Confirmatory Studies

— Diagnostic uncertainty after initial workup

— Young-onset (<65), rapid progression, atypical features, family history suggesting genetic etiology

— Mixed or unclear subtype affecting management

— Patient/family desire for definitive etiologic diagnosis

— Multi-domain battery over 2–4 hours

— Best for distinguishing MCI from normal aging, characterizing subtype, baseline for tracking, medicolegal/capacity questions

— FDG-PET: temporoparietal hypometabolism → AD; frontal/anterior temporal → FTD

— Amyloid PET (florbetapir/flutemetamol/florbetaben): confirms amyloid pathology; now covered by Medicare (2023+) in appropriate-use settings

— Tau PET: emerging, correlates with disease stage

— DaTscan (ioflupane): reduced striatal uptake supports DLB or parkinsonian syndromes (helps distinguish DLB from AD)

— Low Aβ42, high total tau and phospho-tau → AD pattern

— 14-3-3 protein, RT-QuIC → prion disease

— Consider when amyloid PET unavailable

Key distinction: APOE4 is a risk modifier, not diagnostic — routine APOE testing is not recommended for diagnosis or risk stratification in clinical practice outside of anti-amyloid therapy eligibility screening.

When to escalate beyond office screen + basic labs + structural imaging:

Neuropsychological testing (referral to neuropsychologist):

Advanced imaging:

CSF biomarkers (lumbar puncture):

Plasma biomarkers (emerging): p-tau217, p-tau181, Aβ42/40 ratio — increasingly used to triage referrals; not yet routine

EEG: periodic sharp wave complexes (CJD); generalized slowing (encephalopathy); helpful when seizures or rapid decline suspected

Genetic testing: consider in early-onset (<65) with strong family history — APP, PSEN1, PSEN2 (AD); MAPT, GRN, C9orf72 (FTD); huntingtin (HD). Pre/post-test counseling required.

Risk Stratification and Clinical Decision Pathway After a Positive Screen

— Step 1: Confirm not delirium (acute, fluctuating, inattention) → if delirium, treat underlying cause and re-screen after resolution

— Step 2: Confirm not depression → PHQ-9; if positive, treat and reassess in 6–12 weeks

— Step 3: Review medications — STOPP/Beers list; taper anticholinergics, benzodiazepines, opioids, sedating antihistamines, muscle relaxants

— Step 4: Targeted labs (TSH, B12, CMP, CBC) and structural imaging

— Step 5: Functional assessment (IADLs/ADLs) → MCI vs dementia determination

— Step 6: Subtype the dementia clinically (AD, vascular, DLB, FTD, mixed) → guides prognosis and treatment

— Mild: independent ADLs, IADL impairment, MMSE ~21–26

— Moderate: ADL assistance needed, MMSE 10–20

— Severe: total dependence, MMSE <10

— Functional Assessment Staging Tool (FAST) used for hospice eligibility (FAST 7c or beyond + comorbidity supports hospice referral)

— ~10–15% of MCI converts to dementia per year (vs ~1–2% baseline in elderly)

— Higher conversion risk: amnestic subtype, APOE4+, positive amyloid biomarkers, hippocampal atrophy

Step 3 management: After a positive Mini-Cog in clinic, the next best step is NOT to start donepezil. The correct sequence is rule out reversible causes → MRI → labs → functional assessment → subtype → then treat. Anchoring on a drug before this workup is a classic distractor.

Positive screen does NOT equal dementia — false positives common in low-education, non-English-speaking, depressed, or acutely ill patients

Step-by-step Step 3 pathway:

Severity staging (once dementia confirmed):

Risk stratification of MCI progression:

Pharmacotherapy — Symptomatic Treatment of Dementia

— Donepezil: 5 mg QHS → 10 mg after 4–6 weeks; once-daily dosing, best tolerated

— Rivastigmine: oral or transdermal patch (4.6 → 9.5 → 13.3 mg/24h); patch reduces GI side effects; FDA-approved for PD dementia

— Galantamine: 8 → 16 → 24 mg/day

— Adverse effects: nausea, diarrhea, anorexia, weight loss, bradycardia, syncope, vivid dreams, urinary urgency, muscle cramps

— Caution: bradyarrhythmia, sick sinus, peptic ulcer, asthma/COPD

— Memantine 5 → 20 mg/day; add for moderate-to-severe AD (MMSE <15) or combine with donepezil; well tolerated; renal dose adjustment

— Lecanemab (Leqembi) — FDA-approved 2023 for MCI or mild AD due to amyloid-confirmed disease

— Donanemab — approved 2024, similar indication

— Require amyloid PET or CSF confirmation, APOE4 genotyping for risk counseling

— ARIA-E (edema) and ARIA-H (microhemorrhage) are key risks; MRI surveillance required; higher risk in APOE4 homozygotes

— Anticholinergics (diphenhydramine, oxybutynin, TCAs)

— Benzodiazepines, zolpidem

— First-generation antipsychotics for behavior (black box: increased mortality in dementia)

Board pearl: ChEIs provide modest symptomatic benefit — typically ~6–12 month delay in functional decline. Counsel families this is not curative. Discontinue if no benefit at 6–12 months or in severe dementia where burden exceeds benefit.

Cholinesterase inhibitors (ChEIs) — first-line for mild-to-moderate AD, DLB, and PD dementia

NMDA antagonist:

Anti-amyloid monoclonal antibodies (disease-modifying, newer):

Avoid/de-prescribe:

Behavioral Symptoms and Non-Pharmacologic Management

— Describe behavior, Investigate triggers (pain, infection, constipation, hunger, environment), Create plan, Evaluate

— Address unmet needs: untreated UTI, fecal impaction, dental pain, hearing aid batteries

— Structured routine, music therapy, exposure to natural light, reduced stimulation

— Caregiver education and respite (single most effective intervention for nursing home delay)

— Citalopram (≤20 mg in elderly due to QT) — evidence for agitation (CitAD trial)

— Antipsychotics: risperidone, olanzapine, quetiapine, aripiprazole — use lowest dose, shortest duration; black box warning for ↑mortality (stroke, sudden death) in elderly dementia patients

— Brexpiracit (Rexulti) — FDA-approved 2023 specifically for agitation in AD

— Avoid haloperidol in DLB (severe neuroleptic sensitivity — pimavanserin or quetiapine preferred)

— Avoid benzodiazepines except for end-of-life or severe acute agitation

— Melatonin 3–10 mg, sleep hygiene, treat OSA

— Avoid diphenhydramine, zolpidem, trazodone (used cautiously)

CCS pearl: When ordering for an agitated dementia patient, the first orders are vitals, glucose check, UA, basic labs, pain assessment, and bowel/bladder check — before any sedating medication. Reflexively giving lorazepam to a confused elderly patient is a high-yield wrong answer.

BPSD (Behavioral and Psychological Symptoms of Dementia) — agitation, aggression, psychosis, wandering, sleep disturbance — present in up to 90% of patients during disease course

First-line is always non-pharmacologic (DICE approach):

Pharmacologic (only after non-pharm fails and safety threatened):

Sleep:

Driving and firearms: assess at diagnosis and at each visit; refer to OT-based driving evaluation; counsel firearm safety

Special Populations — Elderly, Frailty, Renal/Hepatic Impairment

— Baseline cognitive variability is wide; use age- and education-adjusted norms

— Polypharmacy is the dominant reversible contributor — deprescribing is often the single highest-yield intervention

— Frailty + cognitive impairment increases delirium risk 3–5× during hospitalization

— Memantine requires dose reduction: CrCl 5–29 mL/min → max 5 mg BID

— Galantamine: avoid if CrCl <9; reduce if 9–59

— Donepezil and rivastigmine: no specific renal adjustment, but monitor tolerance

— Galantamine and donepezil are hepatically metabolized — reduce dose in moderate impairment; avoid in severe

— Rivastigmine is non-hepatically metabolized — preferred in hepatic disease

— Baseline ECG before ChEI initiation in patients with syncope, bradyarrhythmia, on rate-controlling agents

— Hold ChEI if HR <50 or new syncope; consider pacemaker evaluation

— Avoid: anticholinergics, benzodiazepines, Z-drugs, first-gen antihistamines, muscle relaxants, TCAs, meperidine

— Use cautiously: SSRIs (hyponatremia/SIADH), antipsychotics, opioids

— HELP protocol (Hospital Elder Life Program): orientation, early mobilization, sleep protocols, vision/hearing aids → reduces delirium 40%

— Post-hospital cognitive screening recommended at 4–6 weeks (recovery from hospital-associated delirium)

Step 3 management: For a frail 88-year-old with mild AD and CrCl 25, the right answer for memantine is 5 mg BID maximum, not standard 10 mg BID. Renal dosing questions are testable specifics.

Very elderly (≥85):

Renal impairment:

Hepatic impairment:

Cardiovascular comorbidity:

Beers Criteria highlights in cognitively impaired elderly:

Hospital-related dementia risk:

Special Populations — Younger-Onset, Cultural/Linguistic, and Down Syndrome

— ~5–10% of dementia; differential broader: autoimmune (anti-NMDA, LGI1), infectious (HIV, syphilis, prion), genetic (FTD, early-onset AD, HD), metabolic (Wilson, leukodystrophy), substance, TBI/CTE

— Earlier referral to neurology and genetics

— Workplace and disability planning (SSDI, FMLA); driving evaluation

— APP gene triplication → >50% develop AD by age 60; begin baseline cognitive assessment at age 35–40 with serial screening (use modified tools like DLD or DSQIID)

— Lecanemab/donanemab not studied; ChEIs commonly used

— MMSE and MoCA are sensitive to education and language; underestimates in <8 years education or non-English-primary patients

— Use culturally adapted tools: RUDAS (Rowland Universal Dementia Assessment Scale), CCCE, validated translations

— Use professional medical interpreter, not family members (especially for capacity discussions)

— Black and Hispanic Americans have 1.5–2× higher dementia prevalence but are diagnosed later and less likely to receive ChEIs or specialty referral

— Address vascular risk factors aggressively (midlife HTN control reduces dementia risk ~17%)

Board pearl: A Spanish-speaking patient with 4 years of education scoring 22/30 on the MMSE may have a normal age/education-adjusted score. Always interpret tools in context before labeling impairment.

Young-onset dementia (<65):

Down syndrome:

Cultural and linguistic considerations:

Health disparities:

Pregnancy: rare overlap; if cognitive symptoms in pregnancy, consider autoimmune encephalitis (anti-NMDA receptor — paraneoplastic ovarian teratoma), eclampsia, PRES, Sheehan

Veterans: higher TBI and PTSD rates; CTE risk; VA covers comprehensive workup

Complications and Adverse Outcomes

— Falls: 2–3× increased risk; fractures (hip, vertebral) drive mortality

— Wandering and elopement: ~60% of community-dwelling dementia patients wander at least once

— Driving accidents: crash risk rises with dementia severity; mandatory assessment

— Medication errors: at home and in transitions of care — leading reversible cause of decompensation

— Firearm injury: assess at every visit

— Fire/cooking accidents, gas leaks, financial exploitation

— Aspiration pneumonia — leading cause of death in late-stage dementia

— Pressure injuries, contractures

— Dehydration and malnutrition — feeding tubes do NOT improve survival or aspiration risk in advanced dementia (avoid)

— Recurrent UTIs — but avoid treating asymptomatic bacteriuria; differentiate from delirium triggers

— Delirium superimposed on dementia — every hospitalization risk

— Depression (40%), apathy (70%), psychosis (30–50% in DLB), anxiety, suicide (especially early post-diagnosis)

— Caregiver depression (40–70%), burnout, higher mortality

— Financial strain; ~70% of dementia care costs are unpaid family labor

— Elder abuse and self-neglect risk

— Median survival 4–8 years from diagnosis (AD); shorter in DLB, vascular, FTD

— Sixth leading cause of death in US (Alzheimer specifically)

Key distinction: In advanced dementia, PEG tubes do not prolong survival, prevent aspiration, or improve quality of life — careful hand-feeding is preferred. This is a high-yield AGS Choosing Wisely point and an ethics-flavored stem.

Functional and safety complications:

Medical complications:

Neuropsychiatric:

Caregiver outcomes:

Mortality:

When to Escalate — Referrals, Hospitalization, and Specialty Care

— Young-onset (<65)

— Rapid progression (months)

— Atypical features: prominent psychosis, parkinsonism, myoclonus, focal deficits

— Diagnostic uncertainty after primary care workup

— Consideration of anti-amyloid therapy (lecanemab/donanemab)

— Genetic counseling needs

— MCI vs normal aging unclear

— Need detailed cognitive profile for subtype or capacity

— Baseline for tracking, return-to-work or legal questions

— Severe BPSD refractory to first-line management

— Suicidality, severe depression with psychotic features

— Capacity evaluation for high-stakes decisions

— Acute delirium with unsafe home environment

— Severe agitation/aggression with safety risk

— Untreated medical condition (UTI, pneumonia, MI, stroke) presenting as cognitive change

— Self-neglect, dehydration, malnutrition

— Suicidality

— Palliative: at any stage with significant symptom burden or goals-of-care discussion needs

— Hospice eligibility: FAST stage 7c or beyond (nonambulatory, ≤6 words, dependent ADLs) PLUS one comorbidity (aspiration pneumonia, sepsis, stage 3–4 ulcer, recurrent fever, weight loss >10%)

— Alzheimer's Association 24/7 helpline (1-800-272-3900)

— Area Agency on Aging, adult day programs, respite care, PACE programs

CCS pearl: For an elderly patient with new confusion presenting to ED, the first orders are not "admit to neurology." Order: vitals, fingerstick, CBC, CMP, UA, CXR, ECG, and reconcile medications. Most "acute dementia" is delirium from a treatable cause.

Refer to neurology, geriatrics, or memory clinic when:

Refer to neuropsychology when:

Refer to psychiatry when:

Indications for hospitalization:

Palliative care / hospice referral:

Social work and community resources:

Key Differentials — Within Neurocognitive Disorders

— Insidious amnestic onset, medial temporal atrophy, low CSF Aβ42 / high tau

— APOE4 risk; amyloid PET positive

— Stepwise decline OR slow progression with executive dysfunction; vascular risk factors; MRI white matter disease, lacunes, cortical strokes

— Treatment: aggressive vascular risk control (BP <130/80, statin, antiplatelet, smoking cessation, glycemic control)

— Core features: fluctuating cognition, visual hallucinations, REM sleep behavior disorder, parkinsonism

— Severe neuroleptic sensitivity — avoid haloperidol/risperidone

— Rivastigmine helpful; DaTscan supports diagnosis

— Cognitive deficits appearing >1 year after established motor PD

— DLB vs PDD: arbitrary 1-year rule

— Behavioral variant: disinhibition, apathy, hyperorality, loss of empathy; age 50–65

— Primary progressive aphasia variants (nonfluent, semantic, logopenic)

— Often spared memory early; MMSE/MoCA may miss early FTD

— AD + vascular is the most common combination in autopsy series; manage both

— Rapidly progressive (weeks-months), myoclonus, ataxia, 14-3-3 in CSF, cortical ribboning on DWI MRI

Key distinction: Early prominent visual hallucinations + parkinsonism + REM sleep behavior disorder = DLB until proven otherwise. Treating these patients with typical antipsychotics can be fatal — a classic Step 3 safety stem.

Alzheimer disease (60–80%):

Vascular dementia / vascular cognitive impairment:

Dementia with Lewy bodies (DLB):

Parkinson disease dementia:

Frontotemporal dementia (FTD):

Mixed dementia:

Creutzfeldt-Jakob disease (prion):

Key Differentials — Reversible and Non-Neurodegenerative Mimics

— Acute (hours-days), fluctuating, inattention, altered consciousness

— Triggers: infection (UTI, pneumonia), medications, electrolytes, hypoxia, withdrawal, pain, urinary retention, fecal impaction

— CAM (Confusion Assessment Method) is screening tool of choice

— Subacute, prominent complaints of memory loss (patient complains more than family), "I don't know" answers, anhedonia, sleep/appetite change

— Improves with antidepressant; PHQ-9 ≥10 triggers treatment

— Anticholinergics (oxybutynin, diphenhydramine, TCAs, paroxetine)

— Benzodiazepines, opioids, gabapentin, z-drugs

— Anticonvulsants (topiramate notorious for cognitive slowing)

— Statins (rare, reversible), PPIs (controversial)

— Hypothyroidism, B12 deficiency, hypercalcemia, hyponatremia, uremia, hepatic encephalopathy

— HIV-associated neurocognitive disorder, neurosyphilis, Lyme, Whipple, JC virus (PML)

— Normal-pressure hydrocephalus (gait + incontinence + cognition; tap test improves gait → VP shunt candidate)

— Chronic subdural hematoma (especially in falls, anticoagulation)

— Brain tumor (frontal meningioma classically)

— Anti-NMDA receptor encephalitis (young women + ovarian teratoma), LGI1, CASPR2, Hashimoto encephalopathy

— Untreated OSA → cognitive impairment that improves with CPAP

— Alcohol use disorder, Wernicke-Korsakoff (thiamine!)

Board pearl: The "treatable dementias" workup — TSH, B12, MRI, ± HIV/RPR — catches a small but critical fraction. Missing a chronic subdural in an anticoagulated faller is a high-yield miss.

Always exclude before labeling "dementia":

Delirium:

Depression ("pseudodementia"):

Medication-induced:

Endocrine/metabolic:

Infectious:

Structural:

Autoimmune/paraneoplastic:

Sleep:

Substance:

Secondary Prevention, Long-Term Plan, and Modifiable Risk Factors

— Midlife: hearing loss (treat with amplification), hypertension, obesity, head injury, excess alcohol, high LDL

— Later life: smoking, depression, social isolation, physical inactivity, diabetes, air pollution, untreated vision loss

— Early life: less education

— BP <130/80 in midlife and later (SPRINT-MIND: intensive BP control reduced MCI 19%)

— Statin for ASCVD prevention per ACC/AHA

— Glycemic control (A1c individualized, ~7–7.5% in elderly)

— AF: anticoagulation reduces stroke and vascular cognitive decline

— Smoking cessation

— Physical activity: ≥150 min/week moderate aerobic + 2 days resistance

— Mediterranean or MIND diet: consistently associated with lower dementia risk

— Sleep: treat OSA (CPAP), aim 7–8 hours

— Cognitive and social engagement: education, social activities, ?cognitive training (modest benefit)

— Alcohol: ≤1 drink/day women, ≤2/day men; abstinence preferred in established cognitive impairment

Step 3 management: When asked the best intervention to reduce future dementia risk in a 55-year-old with HTN and untreated hearing loss, the highest-yield answers are BP control to <130/80 and hearing aids — not memory supplements.

Lancet Commission 2020/2024 — 14 modifiable risk factors accounting for ~40–45% of dementia risk:

Cardiovascular optimization is dementia prevention:

Lifestyle:

Hearing aids: the ACHIEVE trial (2023) showed hearing intervention reduced cognitive decline ~48% in high-risk older adults over 3 years — strongly recommend audiology referral

Vaccinations: influenza, pneumococcal, COVID, shingles — both reduce infection-related delirium and possibly dementia risk (shingles vaccine association emerging)

Avoid supplements without evidence: ginkgo, vitamin E (high-dose), coconut oil — no benefit; potential harms

Follow-Up, Monitoring, and Caregiver Support

— Initial: every 3 months × 1 year to titrate medications, address BPSD, support caregiver

— Stable: every 6 months

— Annual cognitive assessment with same tool (track MoCA/MMSE trajectory)

— Adherence (medications, both dementia and comorbid)

— ADLs/IADLs (functional decline triggers care escalation)

— Affect (depression, anxiety, apathy)

— Agitation/behavior (BPSD)

— Advance care planning

— ChEI: weight, GI symptoms, HR, syncope at each visit

— Memantine: renal function annually

— Antipsychotics: re-evaluate need every 3 months; attempt taper; monitor for EPS, metabolic, QTc, falls

— Anti-amyloid mAbs: MRI surveillance before doses 5, 7, 14 for ARIA-E/H

— Reassess at each visit; refer to on-road OT evaluation if any concerns

— Report per state law (some states mandate physician reporting; know your state)

— Early — while patient retains capacity

— Healthcare proxy/durable POA, living will, POLST/MOLST

— Discuss CPR, intubation, artificial nutrition, hospitalization preferences

— Revisit at each disease stage

— Screen caregiver depression (Zarit Burden Interview, PHQ-9)

— Connect to Alzheimer's Association, support groups, respite care

— Address financial planning, long-term care insurance, Medicaid spend-down

— Hospital discharge is the highest-risk window — medication reconciliation, follow-up within 7–14 days, clear communication with caregiver

CCS pearl: Order advance care planning discussion and caregiver depression screen at every dementia visit on the CCS — these are valid orders that improve patient and caregiver outcomes and are scored favorably.

Follow-up cadence after diagnosis:

At every visit, address the "5 As":

Medication monitoring:

Driving:

Advance care planning:

Caregiver support:

Transitions of care:

Ethical, Legal, and Patient Safety Considerations

— Capacity is decision-specific and time-specific (a patient may have capacity to consent to a flu shot but not to a surgery)

— Four components: understand, appreciate, reason, express a choice

— Diagnosis of dementia ≠ lack of capacity; assess for each decision

— Tools: Aid to Capacity Evaluation (ACE), MacCAT-T

— For research enrollment in moderate-severe dementia, surrogate consent + patient assent required

— Anti-amyloid therapy: complex consent given ARIA risk, infusion burden, modest benefit; document shared decision-making explicitly

— Healthcare proxy/POA → spouse → adult children → parents → siblings (state-specific)

— Apply substituted judgment (what would the patient want?) before best interest standard

— Some states (CA, PA, NJ, OR, NV, DE) mandate physician reporting of dementia or impaired drivers to DMV

— All states allow voluntary reporting; document the conversation

— Mandatory reporting in most states to Adult Protective Services (APS) for suspected abuse, neglect, exploitation

— Cognitive impairment is the largest risk factor for financial exploitation — screen and counsel about scams, joint accounts, POA misuse

— Direct, nonjudgmental counseling at diagnosis; secure or remove firearms; document

— Pre- and post-test counseling mandatory for early-onset/familial workup

— GINA protects employment and health insurance (NOT life/disability insurance)

— Hospital discharge of cognitively impaired patient without caregiver education or follow-up is a sentinel safety event; ensure written instructions, pillbox setup, 7-day follow-up

Board pearl: A patient with mild dementia who refuses a recommended surgery still has the right to refuse if they demonstrate decisional capacity for that decision — diagnosis alone never removes autonomy.

Capacity assessment:

Informed consent edge cases:

Surrogate decision-making hierarchy (when capacity lost and no advance directive):

Driving and reporting:

Elder abuse and self-neglect:

Firearm safety:

Genetic testing ethics:

Transitions of care risk:

High-Yield Associations and Rapid-Fire Facts

Key distinction: USPSTF says "insufficient evidence" — this is NOT "don't screen." Symptomatic patients should always be evaluated; the I statement applies only to asymptomatic universal screening.

USPSTF grade for cognitive screening in asymptomatic ≥65: I (insufficient evidence)

Medicare Annual Wellness Visit: requires detection of cognitive impairment (any validated method)

Best brief office tool: Mini-Cog (3-minute, free, education-resistant)

Best tool for MCI/executive dysfunction: MoCA (<26 abnormal)

Informant-based tool of choice: AD8 (≥2 = concerning)

MCI vs dementia: decided by functional impairment, not test score

Most common reversible contributors: medications, depression, hypothyroidism, B12 deficiency, OSA, alcohol

Required labs: CBC, CMP, TSH, B12; consider HIV/RPR

Required imaging: non-contrast MRI brain (once)

First-line drug class for mild-moderate AD: cholinesterase inhibitors (donepezil, rivastigmine, galantamine)

Add memantine for moderate-severe AD (MMSE <15)

Anti-amyloid mAb risks: ARIA-E and ARIA-H, higher in APOE4 homozygotes

Avoid in DLB: typical antipsychotics (haloperidol) — severe neuroleptic sensitivity

NPH triad: gait apraxia, urinary incontinence, cognitive impairment ("wet, wobbly, wacky")

Hearing loss: single largest modifiable midlife dementia risk factor

SPRINT-MIND: intensive BP control to <120 SBP reduced MCI

PEG tubes in advanced dementia: do NOT improve survival or aspiration — avoid (Choosing Wisely)

Hospice eligibility: FAST 7c + comorbidity

Pseudodementia: depression in elderly — patient complains more than family, "I don't know" answers

Capacity: decision-specific, time-specific; dementia diagnosis does not equal incapacity

Driving reporting: mandatory in 6 states; voluntary elsewhere

Anticholinergic burden: strongest pharmacologic dementia risk factor — deprescribe relentlessly

Board Question Stem Patterns

— 72yo asymptomatic woman at well visit asks about dementia screening

— Answer: Discuss that USPSTF gives an I statement for routine screening; case-find based on patient/family concerns; address modifiable risk factors (BP, hearing, exercise)

— 78yo with family-reported forgetfulness; recalls 1/3 words, abnormal clock

— Next step: NOT donepezil. Order TSH, B12, CMP, CBC, MRI brain; screen for depression and medication review

— Acute confusion, fluctuating, inattention in hospitalized elder

— Answer: Delirium — find and treat the cause (UTI, meds, electrolytes); don't start ChEI

— Patient with fluctuating cognition, visual hallucinations, parkinsonism, agitated in ED

— Wrong: haloperidol. Right: treat underlying trigger, low-dose quetiapine or pimavanserin if needed

— Elderly with gait apraxia, incontinence, cognitive decline, ventriculomegaly on CT

— Answer: High-volume LP (tap test) → if gait improves, refer for VP shunt

— Recent widow, prominent memory complaints, sleep/appetite changes, "I don't know" answers

— Answer: PHQ-9; start SSRI; reassess cognition after depression treated

— 68yo with mild AD, amyloid-confirmed, considering lecanemab

— Best next step: APOE genotyping for ARIA risk counseling; baseline MRI; shared decision-making

— Mild dementia patient refuses recommended pacemaker

— Answer: Assess capacity for this specific decision; if intact, honor refusal

— Moderate dementia, recent crashes

— Answer: Refer to on-road OT driving evaluation; counsel cessation; document; report per state law

— Severe AD, recurrent aspiration, family asks about PEG

— Answer: Recommend careful hand-feeding; PEG does not improve outcomes; palliative care consult

Step 3 management: The recurring theme — rule out reversible causes, assess function, support caregivers, plan ahead, rather than reflexively prescribing.

Stem 1 — The USPSTF question:

Stem 2 — Mini-Cog in clinic:

Stem 3 — Delirium vs dementia:

Stem 4 — DLB safety:

Stem 5 — NPH:

Stem 6 — Pseudodementia:

Stem 7 — Anti-amyloid candidate:

Stem 8 — Capacity:

Stem 9 — Driving:

Stem 10 — Advanced dementia and feeding:

One-Line Recap

Cognitive screening in asymptomatic older adults carries a USPSTF "I" (insufficient evidence) grade, but case-finding with brief validated tools (Mini-Cog, MoCA, AD8) is warranted whenever patients or families raise concerns, with positive screens triggering a structured workup for reversible causes (medications, depression, B12, TSH, MRI) before a clinical diagnosis of MCI or dementia is made and management individualized.

Board pearl: If you remember only one thing for Step 3 — USPSTF "I" does not mean "don't screen"; it means screen based on clinical judgment and concerns, and always investigate reversible contributors before labeling a patient with dementia.

Screening grade: USPSTF = I statement in asymptomatic ≥65; Medicare AWV requires detection — both true

Best brief tools: Mini-Cog (3 min, education-resistant), MoCA (<26 abnormal, best for MCI/executive), AD8 (informant-based)

Diagnostic pipeline after positive screen: rule out delirium → screen depression → deprescribe → labs (CBC, CMP, TSH, B12) → MRI → functional assessment → subtype → treat

MCI vs dementia is defined by function, not score; PEG tubes don't help advanced dementia; never give haloperidol in DLB; hearing aids and BP control are the highest-yield prevention; capacity is decision-specific even with a dementia diagnosis